Can Lercanidipine Be Used for Chronic Coronary Syndrome?
Yes, lercanidipine can be used for chronic coronary syndrome (CCS) as it is a calcium channel blocker (CCB), and CCBs are explicitly recommended as first-line antianginal therapy for most patients with CCS. 1
Guideline-Based Recommendation
The 2024 ESC Guidelines for the Management of Chronic Coronary Syndromes provide clear direction on antianginal drug selection 1:
- Initial treatment with beta-blockers and/or CCBs to control heart rate and symptoms is recommended for most patients with CCS (Class I, Level B recommendation)
- The selection of antianginal drugs should be tailored to patient characteristics, comorbidities, concomitant medications, treatment tolerability, and underlying pathophysiology of angina
Lercanidipine, as a dihydropyridine CCB, fits squarely within this recommendation framework.
Specific Advantages of Lercanidipine in CCS
Combination Therapy Strategy
When monotherapy is insufficient, the combination of a beta-blocker with a dihydropyridine CCB (like lercanidipine) is appropriate for most patients 1. This is particularly relevant because:
- Non-dihydropyridine CCBs (verapamil, diltiazem) cannot be combined with certain drugs like ivabradine
- Dihydropyridines are preferred when combining with beta-blockers due to their complementary mechanisms
Clinical Evidence Supporting Use
Research demonstrates lercanidipine's anti-ischemic efficacy in CCS:
- Significantly increases time to onset of ST segment depression ≥1 mm during exercise testing 2
- Does not cause reflex adrenergic activation, avoiding the negative cardiovascular effects associated with short-acting dihydropyridines 2
- Demonstrates potent protective effects on ischemic ECG changes in experimental angina models 3
Practical Application Algorithm
Step 1: Initial Assessment
- Evaluate heart rate and blood pressure
- Assess for contraindications to CCBs (severe heart failure with reduced ejection fraction)
- Consider comorbidities (hypertension favors CCB use)
Step 2: First-Line Selection
- Either beta-blocker OR CCB (including lercanidipine) as monotherapy 4
- Choose lercanidipine specifically if:
- Patient has hypertension requiring treatment
- Beta-blockers are contraindicated (sick sinus syndrome, AV block, severe PAD, COPD)
- Patient has low baseline heart rate
Step 3: Escalation if Needed
- If symptoms persist on monotherapy, combine lercanidipine with a beta-blocker 1
- This combination is the preferred dual therapy approach for most patients
Important Caveats
When to Exercise Caution
- Heart failure with reduced ejection fraction (HFrEF): CCBs require caution in this population 1
- Severe hypotension or very low blood pressure at baseline
- Significant hepatic impairment (lercanidipine is lipophilic and hepatically metabolized)
What Lercanidipine Does NOT Replace
Lercanidipine addresses symptom control but does not replace:
- Aspirin 75-100 mg daily for event prevention (Class I recommendation) 1
- High-intensity statin therapy for lipid lowering 1
- SGLT2 inhibitors or GLP-1 receptor agonists in select high-risk patients 4
- ACE inhibitors in patients with LV dysfunction, diabetes, or hypertension 1
Recent Evidence on Long-Term Outcomes
A 2017 nationwide cohort study showed lercanidipine was superior to nifedipine in reducing incident stroke over 6 years (adjusted HR 0.526,95% CI 0.347-0.797) 5. While this wasn't specifically in a CCS population, it supports the safety and efficacy of lercanidipine in cardiovascular disease management.
Bottom Line
Lercanidipine is an appropriate and guideline-supported choice for CCS management, either as monotherapy or in combination with a beta-blocker, particularly when blood pressure control is also needed. The 2024 ESC guidelines place CCBs on equal footing with beta-blockers as first-line antianginal therapy, and lercanidipine's dihydropyridine properties make it especially suitable for combination strategies 1.